A short-seller report weighed on the Chinese biotech's shares last month.
News & Analysis: BeiGene
China's biopharma gem drifted lower in the first half of 2019, but there's no identifiable explanation or cause for concern.
Technology, drugs, and energy...here are three Chinese stocks from three different industries that you should be watching today.
China's biotech industry is growing quickly, and the innovative BeiGene could be an opportunity in the space.
Shares tumble in response to an industry megamerger.
Whether you're in the U.S. or China, immuno-oncology is one of the hottest areas in biotech right now.
A third-quarter report and a couple of priority reviews from the China Food and Drug Administration encouraged investors.
A slew of investor updates last month added about $2 billion to the company's market cap.
It hasn't yet received a lot of media attention, but BeiGene has an absolutely huge opportunity in China's nascent biotechnology market.
Find out how these companies have defied a choppy market.